Category: Health Science
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
Perimeter Medical Imaging AI (PINK.V) isn’t messing about: Let’s make breast cancer treatment better – and profitable!
In the North American biotech space, you hear a lot of ‘promise’ from companies and their teams. Lots of ‘we’re going to take this to trial’, and a lot of ‘billion dollar industry’ talk. Lots of early stage bets, a little over-hype perhaps. For the most part, you’re being asked to invest in technologies that…
-
Perimeter Medical Imaging AI (PINK.V) shuffles the deck
PINK is accelerating toward the commercialisation of the OTIS platform. It has already received a $7.4 million grant (non-dilutive capital) from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the ATLAS AI Project.
-
NeuPath Health Inc (NPTH.V): Where a little attention could go a long way
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in Well Health Technologies (WELL.T) (nothing against $WELL!), and I would have been a couple of thousand dollars richer. If only there was a way to prove that. Allow me: It…
-
Aequus Pharmaceuticals (AQS.V) gets Health Canada device licence approval, validates business model
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a wider market, has announced another win Monday morning with news Health Canada has approved the advancing of their Evolve dry-eye relief gel line to an easy-squeeze eye drop bottle. Admittedly,…
-
![How Sixth Wave (SIXW.C) plans to “protect and detect” for COVID-19]()
How Sixth Wave (SIXW.C) plans to “protect and detect” for COVID-19
Sixth Wave is a nanotechnology company focusing on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs).
-
Revive (RVV.C) gives update on FDA Phase 3 clinical trial
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions.
-
Bio-tech without the dice roll: Aequus Pharmaceuticals (AQS.V) building a solid, multi-pronged revenue earner
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with more upside, with less downside. Promise that a team will do more, or do better, or do something – anything. Promise that, if the planets align, something big will come.…
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
Perimeter Medical Imaging AI (PINK.V) untapped value in medtech
Investing your money in health or medical companies is difficult. The complexity of the science often deters investors from allocating a portion of their portfolio to said industry, despite those companies having proven potential to provide the largest gains for its investors. We’re not criticizing – everyone knows that medical terminology is only second to…
